Chohreh Partovian, MD, PhD

All posts by Chohreh Partovian, MD, PhD

August 18th, 2013

What Patterns of Change in the Use of Nesiritide Reveal About Hospitals as Learning Organizations

Chohreh Partovian discusses her research group’s study of how hospitals varied in their responses to safety concerns about nesiritide from 2005 to 2010.

July 25th, 2012

DES in Patients at Low Risk for TVR: Is the Benefit Worth the Cost? (Part I)

, , , and

In a recent article in Archives of Internal Medicine, researchers performed an analysis of current use of drug-eluting stents (DES) in patients at various levels of risk for target-vessel revascularization (TVR), and estimated the cost and clinical outcomes of using BMS rather than DES in patients at low risk (see News). To gauge reaction to […]

April 24th, 2012

Primary PCI Meta-Analysis: Mortality Trumps All

In a new meta-analysis Dr. Gregg Stone and members of the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation concluded that reduction in target-vessel revascularization (TVR) associated with drug-eluting stents (DES) in primary PCI provided a powerful reason for continued use of DES in primary PCI. An accompanying editorial by James Brophy focused on several potential DES weaknesses in the study. […]